MTOR and acute myeloid leukemia: ERKNet recommendations for kidney involvement in TSC suggest biopsy in cases of fat-poor AML growing at a rate of at least 5 mm/year and/or unresponsive to mTOR inhibitor therapy, with surgical intervention indicated in cases of histopathologically confirmed RCC [44].